GKOS vs. TARS
GKOS (Glaukos Corporation) and TARS (Tarsus Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — GKOS in Medical Devices, TARS in Biotechnology. Over the past 5 years, GKOS returned 14.84%/yr vs 14.75%/yr for TARS. At a 0.27 correlation, their price movements are largely independent.
Performance
GKOS vs. TARS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GKOS achieves a 35.26% return, which is significantly higher than TARS's -28.99% return.
GKOS
- 1D
- -1.52%
- 1M
- 20.43%
- 6M
- 35.25%
- YTD
- 35.26%
- 1Y
- 47.11%
- 3Y*
- 28.95%
- 5Y*
- 14.84%
- 10Y*
- 17.79%
TARS
- 1D
- -9.35%
- 1M
- -6.15%
- 6M
- -24.37%
- YTD
- -28.99%
- 1Y
- 48.39%
- 3Y*
- 49.19%
- 5Y*
- 14.75%
- 10Y*
- —
GKOS vs. TARS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
GKOS Glaukos Corporation | 35.26% | -24.70% | 88.63% | 81.98% | -1.71% | -40.95% | 37.46% |
TARS Tarsus Pharmaceuticals, Inc. | -28.99% | 47.88% | 173.43% | 38.13% | -34.84% | -45.56% | 155.12% |
Correlation
The correlation between GKOS and TARS is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.27 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Oct 16, 2020 | 0.27 |
Fundamentals
GKOS:
$8.97B
TARS:
$2.50B
GKOS:
-$3.29
TARS:
-$1.13
GKOS:
15.94
TARS:
4.65
GKOS:
13.21
TARS:
7.16
GKOS:
$551.35M
TARS:
$535.08M
GKOS:
$439.11M
TARS:
$483.93M
GKOS:
-$158.75M
TARS:
-$39.55M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GKOS vs. TARS — Risk / Return Rank
GKOS
TARS
GKOS vs. TARS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Glaukos Corporation (GKOS) and Tarsus Pharmaceuticals, Inc. (TARS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GKOS | TARS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.07 | ||
| Sortino ratioReturn per unit of downside risk | -0.02 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.18 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | 1.53 | 1.36 | +0.17 |
| Martin ratioReturn relative to average drawdown | 3.42 | 2.77 | +0.64 |
Loading charts...
Drawdowns
GKOS vs. TARS - Drawdown Comparison
The maximum GKOS drawdown since its inception was -69.57%, smaller than the maximum TARS drawdown of -77.67%. Use the drawdown chart below to compare losses from any high point for GKOS and TARS.
Loading charts...
Drawdown Indicators
| GKOS | TARS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -69.57% | -77.67% | +8.10% |
Max Drawdown (1Y)Largest decline over 1 year | -28.39% | -30.42% | +2.03% |
Max Drawdown (3Y)Largest decline over 3 years | -53.68% | -47.28% | -6.40% |
Max Drawdown (5Y)Largest decline over 5 years | -53.68% | -62.67% | +8.99% |
Max Drawdown (10Y)Largest decline over 10 years | -69.57% | — | — |
Current DrawdownCurrent decline from peak | -5.27% | -29.54% | +24.27% |
Average DrawdownAverage peak-to-trough decline | -27.67% | -40.29% | +12.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.57% | 14.92% | -1.35% |
Volatility
GKOS vs. TARS - Volatility Comparison
The current volatility for Glaukos Corporation (GKOS) is 10.96%, while Tarsus Pharmaceuticals, Inc. (TARS) has a volatility of 18.03%. This indicates that GKOS experiences smaller price fluctuations and is considered to be less risky than TARS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GKOS | TARS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.96% | 18.03% | -7.07% |
Volatility (6M)Calculated over the trailing 6-month period | 41.83% | 32.76% | +9.07% |
Volatility (1Y)Calculated over the trailing 1-year period | 53.14% | 46.45% | +6.69% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 50.53% | 58.78% | -8.25% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 52.40% | 64.80% | -12.40% |
Dividends
GKOS vs. TARS - Dividend Comparison
Neither GKOS nor TARS has paid dividends to shareholders.
Financials
GKOS vs. TARS - Financials Comparison
This section allows you to compare key financial metrics between Glaukos Corporation and Tarsus Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GKOS vs. TARS - Profitability Comparison
GKOS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Glaukos Corporation reported a gross profit of 117.23M and revenue of 150.57M. Therefore, the gross margin over that period was 77.9%.
TARS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Tarsus Pharmaceuticals, Inc. reported a gross profit of 152.66M and revenue of 162.05M. Therefore, the gross margin over that period was 94.2%.
GKOS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Glaukos Corporation reported an operating income of -19.86M and revenue of 150.57M, resulting in an operating margin of -13.2%.
TARS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Tarsus Pharmaceuticals, Inc. reported an operating income of -6.12M and revenue of 162.05M, resulting in an operating margin of -3.8%.
GKOS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Glaukos Corporation reported a net income of -19.78M and revenue of 150.57M, resulting in a net margin of -13.1%.
TARS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Tarsus Pharmaceuticals, Inc. reported a net income of -6.97M and revenue of 162.05M, resulting in a net margin of -4.3%.
Frequently Asked Questions
GKOS and TARS have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TARS has higher volatility (18.03%) compared to GKOS (10.96%). In terms of maximum drawdown, GKOS dropped -69.57% vs TARS's -77.67%.
TARS currently has the higher Sharpe Ratio (0.89 vs 0.82), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GKOS and TARS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer